Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsPreferred Shares IssuedShort-Term Debt repayments
Ratios

Mangoceuticals (MGRX) EBIAT (2023 - 2025)

Mangoceuticals' EBIAT history spans 3 years, with the latest figure at -$7.6 million for Q3 2025.

  • For Q3 2025, EBIAT fell 281.08% year-over-year to -$7.6 million; the TTM value through Sep 2025 reached -$19.8 million, down 112.55%, while the annual FY2024 figure was -$8.7 million, 5.5% up from the prior year.
  • EBIAT for Q3 2025 was -$7.6 million at Mangoceuticals, down from -$5.4 million in the prior quarter.
  • Across five years, EBIAT topped out at -$1.8 million in Q3 2023 and bottomed at -$7.6 million in Q3 2025.
  • The 3-year median for EBIAT is -$2.4 million (2024), against an average of -$3.3 million.
  • The largest annual shift saw EBIAT grew 24.13% in 2024 before it plummeted 281.08% in 2025.
  • A 3-year view of EBIAT shows it stood at -$2.6 million in 2023, then grew by 24.13% to -$1.9 million in 2024, then tumbled by 291.04% to -$7.6 million in 2025.
  • Per Business Quant, the three most recent readings for MGRX's EBIAT are -$7.6 million (Q3 2025), -$5.4 million (Q2 2025), and -$4.8 million (Q1 2025).